Advertisement
Collaboration › Details
Abingworth–Goodwin Procter: legal services, 201807 supply service legal counsel for $315m Abingworth Bioventures VII Fund
Period | 2018-07-09 | |
Partner, 1st | Abingworth Bioventures VII (ABV VII) | |
Group | Carlyle (Group) | |
Partner, 2nd | Goodwin Procter LLP | |
Group | Goodwin Procter (Goowin Law) (Group) | |
Product | legal services | |
Product 2 | Abingworth Bioventures VII (ABV VII) | |
Abingworth LLP. (7/9/18). "Press Release: Abingworth Raises $315m for ABV VII 12th Life Sciences Fund". London.
Abingworth, the international investment group dedicated to life sciences, today announced the final closing of its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. ABV VII exceeded its target of $300 million and is Abingworth's 12th fund, investing in life sciences companies in Europe and the US. The firm has funds under management of over $1.2 billion.
The fund invests broadly across all stages of development including early and late-stage venture deals, Clinical Co-development, VIPEs (Venture Investments in Public Equities) and public equities. Investment size per company will typically range from $15 million to $30 million.
"We are delighted to have raised this new fund and to be supported by such high-quality existing and new investors," said Tim Haines, Managing Partner. "This is an exciting time in medical and scientific innovation to launch our new fund and we look forward to building on our recent achievements."
Recent exits include the acquisitions of Wilson Therapeutics by Alexion and of IFM Therapeutics by Bristol-Myers Squibb. Abingworth's funds have also benefited from the rapid progress made by companies such as CRISPR Therapeutics (NASDAQ: CRSP) since investing in the Series A, as well as from GammaDelta Therapeutics, which was seeded by Abingworth and incubated in its London office. In addition, its Clinical Co-Development portfolio has driven significant value with Avillion's approval of BOSULIF® and SFJ Pharmaceuticals' approvals of MYLOTARG® and BESPONSA®.
"We believe that Abingworth's transatlantic presence has contributed significantly to our successful life sciences strategy," said Kurt von Emster, Managing Partner. "It has increased deal flow and expanded access to markets as well as broadened our network of entrepreneurs, management and investors."
Abingworth's investor base has further diversified for ABV VII, including capital from endowments, foundations, fund-of-funds, family offices, healthcare corporations, insurance companies and pension plans across the US, Europe and Asia.
Asante Capital Group acted as placement agent for ABV VII. Goodwin Procter acted as legal counsel.
Notes for Editors
About Abingworth
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1.2 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life science sectors.
Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in 148 life science companies, leading to 65 IPOs and 46 mergers and acquisitions.
Clinical Co-development
Abingworth has pioneered the Clinical Co-development approach. This model provides financing for late-stage therapeutic assets with the co-development company incurring all the clinical and regulatory risk. The co-development company receives a pre-negotiated return once the drug is approved. Abingworth has made nine clinical co-development investments through its portfolio companies, Avillion and SFJ Pharmaceuticals.
VIPEs
A VIPE (Venture Investment in Public Equity) is a venture-style investment in a small public company. Abingworth invests in a significant holding, takes a board seat, and plays an active role in developing the business. We support the company in the same way as a venture investment, providing access to our expertise and networks as required.
http://www.abingworth.com
Record changed: 2018-07-10 |
Advertisement
More documents for Carlyle (Group)
- [1] Abingworth LLP. (10/30/23). "Press Release: Abingworth Raises $356 Million for New Clinical Co-Development Co-Investment Fund (CCD-CIF)". London & New York, NY....
- [2] Carlyle Group, The. (4/11/22). "Press Release: Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth". New York, NY....
- [3] Glycomine, Inc.. (12/17/21). "Press Release: Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease". San Carlos, CA....
- [4] Anjarium Biosciences AG. (9/16/21). "Press Release: Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies". Schlieren....
- [5] Abingworth LLP. (9/15/21). "Press Release: Abingworth Strengthens Investment Team with New Appointments in the US and UK". London....
- [6] Inova Software S.A.S.. (7/1/21). "Press Release: Carlyle Partners with Inova. Growth Equity Transaction to Support Inova’s Ambition to Become the Leading Platform for Life Science Collaborations". Lyon....
- [7] Abingworth LLP. (5/10/21). "Press Release: Abingworth Raises $582 Million for New Clinical Co-Development Fund – ACCD 2". London....
- [8] Abingworth LLP. (2/3/21). "Press Release: Abingworth Raises $465m for New Life Sciences Fund Abingworth Bioventures 8". London....
- [9] GHO Capital Partners LLP. (6/3/20). "Press Release: GHO Capital Acquires X-Chem, a Leading Drug Discovery Service Provider". London....
- [10] Emulate, Inc.. (3/19/20). "Press Release: Emulate, Inc. Appoints Jim Corbett as Chief Executive Officer and Martin Madaus, PhD, as Executive Chairman". Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top